Therapy Areas
Latest News
Boston Scientific receives FDA clearance for Asurys fluid management system
...
Edwards Lifesciences reports positive two-year data for EVOQUE valve system
30 March 2026 - Structural heart innovation company Edwards Lifesciences (NYSE: EW) on Monday reported new two-year data from its TRISCEND II randomised trial demonstrating sustained clinical benefits for its EVOQUE transcatheter tricuspid valve repl...
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
30 March 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that China's National Medical Products Administration has accepted for review a new drug application for bepirovirsen, an investigational antisense olig...
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
30 March 2026 - Cardiothoracic imaging software provider 4DMedical Limited (ASX: 4DX) declared on Monday that it has received CE Mark certification for its CT:VQ imaging technology, enabling commercial deployment across the European Union, as the com...
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
30 March 2026 - Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), a biopharmaceutical company focused on autoimmune diseases, announced on Monday that it has entered into a definitive merger agreement to acquire Kezar Life Sciences Inc (NASDAQ:KZR), a biote...
GXO appointed to manage NHS England bowel cancer home testing kits
...
Amgen reports Repatha (evolocumab) cuts risk of first major CV events by 31% in high-risk patients without known significant atherosclerosis
30 March 2026 - US biopharmaceutical company Amgen (NASDAQ:AMGN) announced on Saturday that Repatha (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse ...